Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E

Z. Borok, A. Gillissen, R. Buhl, R. F. Hoyt, R. C. Hubbard, T. Ozaki, S. I. Rennard, Ronald Crystal

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Prostaglandin E (PGE), a cyclooxygenase metabolite normally present in high concentrations in respiratory epithelial lining fluid (ELF), is capable of suppressing mesenchymal cell proliferation mediated by polypeptide-derived growth factors. Although PGE is normally abundant in respiratory ELF, PGE levels in ELF of individuals with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disorder characterized by intraalveolar mesenchymal cell accumulation and fibrosis, were found to be 50% lower than normal (p < 0.01): that is, a relative PGE 'deficiency' in ELF may enhance intraalveolar mesenchymal cell proliferation in IPF. With this background, it is rational to consider augmenting PGE levels in ELF as a future therapy for IPF. Since systemic administration of PGE is associated with significant adverse effects, in vitro and experimental animal studies were carried out to evaluate whether aerosol PGE administration could augment ELF PGE levels. Greater than 50% of a solution of PGE1, could be placed in droplets < 3 μm mass median aerodynamic diameter without loss of function. Aerosolization of PGE1 to sheep (n = 14) resulted in a marked augmentation of ELF PGE1 levels (preaerosol 20 ± 7 nM, 30 min postaerosol 1,150 ± 210 nM; p < 0.0 to 0.1). ELF PGE1 levels remained elevated for up to 2 h (p < 0.05 compared with baseline) and returned to baseline by 3 h (p > 0.2). Lung interstitial fluid (lymph) PGE1 levels increased slightly, but to levels far less than ELF levels (preaerosol 7 ± 1 nM, 30 min postaerosol 13 ± 2 nM; p < 0.1), and plasma PGE1 levels did not change (p > 0.1). No systemic adverse effects were observed. The PGE1 deposited on the alveolar epithelial surface was functional as evidenced by the ability of ELF recovered 30 min postaerosol to suppress lung fibroblast proliferation compared with pretherapy ELF (p < 0.001). Thus, it is possible to significantly augment the levels of functional PGE1 in lung ELF by aerosolization, suggesting a potential form of therapy to suppress intraalveolar mesenchymal cell accumulation in respiratory ELF PGE deficiency disorders, such as IPF.

Original languageEnglish
Pages (from-to)1080-1084
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume144
Issue number5
DOIs
Publication statusPublished - 1 Jan 1991
Externally publishedYes

Fingerprint

Prostaglandins E
Aerosols
Alprostadil
Lung
Idiopathic Pulmonary Fibrosis
Extracellular Fluid
Lymph
Prostaglandin-Endoperoxide Synthases
Intercellular Signaling Peptides and Proteins
Fibrosis
Fibroblasts
Cell Proliferation
Peptides
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. / Borok, Z.; Gillissen, A.; Buhl, R.; Hoyt, R. F.; Hubbard, R. C.; Ozaki, T.; Rennard, S. I.; Crystal, Ronald.

In: American Review of Respiratory Disease, Vol. 144, No. 5, 01.01.1991, p. 1080-1084.

Research output: Contribution to journalArticle

Borok, Z. ; Gillissen, A. ; Buhl, R. ; Hoyt, R. F. ; Hubbard, R. C. ; Ozaki, T. ; Rennard, S. I. ; Crystal, Ronald. / Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. In: American Review of Respiratory Disease. 1991 ; Vol. 144, No. 5. pp. 1080-1084.
@article{9077dca6f5ff4503a67fe823c5f280c6,
title = "Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E",
abstract = "Prostaglandin E (PGE), a cyclooxygenase metabolite normally present in high concentrations in respiratory epithelial lining fluid (ELF), is capable of suppressing mesenchymal cell proliferation mediated by polypeptide-derived growth factors. Although PGE is normally abundant in respiratory ELF, PGE levels in ELF of individuals with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disorder characterized by intraalveolar mesenchymal cell accumulation and fibrosis, were found to be 50{\%} lower than normal (p < 0.01): that is, a relative PGE 'deficiency' in ELF may enhance intraalveolar mesenchymal cell proliferation in IPF. With this background, it is rational to consider augmenting PGE levels in ELF as a future therapy for IPF. Since systemic administration of PGE is associated with significant adverse effects, in vitro and experimental animal studies were carried out to evaluate whether aerosol PGE administration could augment ELF PGE levels. Greater than 50{\%} of a solution of PGE1, could be placed in droplets < 3 μm mass median aerodynamic diameter without loss of function. Aerosolization of PGE1 to sheep (n = 14) resulted in a marked augmentation of ELF PGE1 levels (preaerosol 20 ± 7 nM, 30 min postaerosol 1,150 ± 210 nM; p < 0.0 to 0.1). ELF PGE1 levels remained elevated for up to 2 h (p < 0.05 compared with baseline) and returned to baseline by 3 h (p > 0.2). Lung interstitial fluid (lymph) PGE1 levels increased slightly, but to levels far less than ELF levels (preaerosol 7 ± 1 nM, 30 min postaerosol 13 ± 2 nM; p < 0.1), and plasma PGE1 levels did not change (p > 0.1). No systemic adverse effects were observed. The PGE1 deposited on the alveolar epithelial surface was functional as evidenced by the ability of ELF recovered 30 min postaerosol to suppress lung fibroblast proliferation compared with pretherapy ELF (p < 0.001). Thus, it is possible to significantly augment the levels of functional PGE1 in lung ELF by aerosolization, suggesting a potential form of therapy to suppress intraalveolar mesenchymal cell accumulation in respiratory ELF PGE deficiency disorders, such as IPF.",
author = "Z. Borok and A. Gillissen and R. Buhl and Hoyt, {R. F.} and Hubbard, {R. C.} and T. Ozaki and Rennard, {S. I.} and Ronald Crystal",
year = "1991",
month = "1",
day = "1",
doi = "10.1164/ajrccm/144.5.1080",
language = "English",
volume = "144",
pages = "1080--1084",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E

AU - Borok, Z.

AU - Gillissen, A.

AU - Buhl, R.

AU - Hoyt, R. F.

AU - Hubbard, R. C.

AU - Ozaki, T.

AU - Rennard, S. I.

AU - Crystal, Ronald

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Prostaglandin E (PGE), a cyclooxygenase metabolite normally present in high concentrations in respiratory epithelial lining fluid (ELF), is capable of suppressing mesenchymal cell proliferation mediated by polypeptide-derived growth factors. Although PGE is normally abundant in respiratory ELF, PGE levels in ELF of individuals with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disorder characterized by intraalveolar mesenchymal cell accumulation and fibrosis, were found to be 50% lower than normal (p < 0.01): that is, a relative PGE 'deficiency' in ELF may enhance intraalveolar mesenchymal cell proliferation in IPF. With this background, it is rational to consider augmenting PGE levels in ELF as a future therapy for IPF. Since systemic administration of PGE is associated with significant adverse effects, in vitro and experimental animal studies were carried out to evaluate whether aerosol PGE administration could augment ELF PGE levels. Greater than 50% of a solution of PGE1, could be placed in droplets < 3 μm mass median aerodynamic diameter without loss of function. Aerosolization of PGE1 to sheep (n = 14) resulted in a marked augmentation of ELF PGE1 levels (preaerosol 20 ± 7 nM, 30 min postaerosol 1,150 ± 210 nM; p < 0.0 to 0.1). ELF PGE1 levels remained elevated for up to 2 h (p < 0.05 compared with baseline) and returned to baseline by 3 h (p > 0.2). Lung interstitial fluid (lymph) PGE1 levels increased slightly, but to levels far less than ELF levels (preaerosol 7 ± 1 nM, 30 min postaerosol 13 ± 2 nM; p < 0.1), and plasma PGE1 levels did not change (p > 0.1). No systemic adverse effects were observed. The PGE1 deposited on the alveolar epithelial surface was functional as evidenced by the ability of ELF recovered 30 min postaerosol to suppress lung fibroblast proliferation compared with pretherapy ELF (p < 0.001). Thus, it is possible to significantly augment the levels of functional PGE1 in lung ELF by aerosolization, suggesting a potential form of therapy to suppress intraalveolar mesenchymal cell accumulation in respiratory ELF PGE deficiency disorders, such as IPF.

AB - Prostaglandin E (PGE), a cyclooxygenase metabolite normally present in high concentrations in respiratory epithelial lining fluid (ELF), is capable of suppressing mesenchymal cell proliferation mediated by polypeptide-derived growth factors. Although PGE is normally abundant in respiratory ELF, PGE levels in ELF of individuals with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disorder characterized by intraalveolar mesenchymal cell accumulation and fibrosis, were found to be 50% lower than normal (p < 0.01): that is, a relative PGE 'deficiency' in ELF may enhance intraalveolar mesenchymal cell proliferation in IPF. With this background, it is rational to consider augmenting PGE levels in ELF as a future therapy for IPF. Since systemic administration of PGE is associated with significant adverse effects, in vitro and experimental animal studies were carried out to evaluate whether aerosol PGE administration could augment ELF PGE levels. Greater than 50% of a solution of PGE1, could be placed in droplets < 3 μm mass median aerodynamic diameter without loss of function. Aerosolization of PGE1 to sheep (n = 14) resulted in a marked augmentation of ELF PGE1 levels (preaerosol 20 ± 7 nM, 30 min postaerosol 1,150 ± 210 nM; p < 0.0 to 0.1). ELF PGE1 levels remained elevated for up to 2 h (p < 0.05 compared with baseline) and returned to baseline by 3 h (p > 0.2). Lung interstitial fluid (lymph) PGE1 levels increased slightly, but to levels far less than ELF levels (preaerosol 7 ± 1 nM, 30 min postaerosol 13 ± 2 nM; p < 0.1), and plasma PGE1 levels did not change (p > 0.1). No systemic adverse effects were observed. The PGE1 deposited on the alveolar epithelial surface was functional as evidenced by the ability of ELF recovered 30 min postaerosol to suppress lung fibroblast proliferation compared with pretherapy ELF (p < 0.001). Thus, it is possible to significantly augment the levels of functional PGE1 in lung ELF by aerosolization, suggesting a potential form of therapy to suppress intraalveolar mesenchymal cell accumulation in respiratory ELF PGE deficiency disorders, such as IPF.

UR - http://www.scopus.com/inward/record.url?scp=0025985547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025985547&partnerID=8YFLogxK

U2 - 10.1164/ajrccm/144.5.1080

DO - 10.1164/ajrccm/144.5.1080

M3 - Article

VL - 144

SP - 1080

EP - 1084

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -